O
Otto C. Boerman
Researcher at Radboud University Nijmegen
Publications - 358
Citations - 17532
Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Epidermal growth factor receptor imaging in human head and neck cancer xenografts
TL;DR: Preclinical studies have shown that radioresistant tumors had a higher tracer uptake after irradiation, probably due to upregulation of membranous EGFR, thereby increasing target availability possibly as a compensation mechanism.
Book ChapterDOI
Monoclonal antibody therapy of kidney cancer.
Egbert Oosterwijk,Adrienne H. Brouwers,Otto C. Boerman,Steven M. Larson,Lloyd J. Old,Peter F.A. Mulders,Chaitanya R. Divgi +6 more
TL;DR: There is a clear need for effective treatment of metastasized Renal Cell Carcinoma, which is not radiosensitive, resistant to chemotherapy, and treatment with biological response modifiers (IL-2, IFN) leads to low response rates.
Journal ArticleDOI
Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin.
TL;DR: The application of WBH or rtPA in combination with adjuvant RIT after CS for the treatment of PC of colonic was feasible but did not significantly potentiate the efficacy of RIT.
Journal ArticleDOI
Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery.
TL;DR: The challenges and the opportunities of using radiolabeled antibodies for image-guided drug delivery are discussed and exciting opportunities are at the horizon by using antibodies as multimodal vehicles carrying both a diagnostic agent and a therapeutic agent.
Journal ArticleDOI
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin
Manuel J. Koppe,Wim J.G. Oyen,Robert P. Bleichrodt,Thijs Hendriks,Albert A.J. Verhofstad,David M. Goldenberg,Otto C. Boerman +6 more
TL;DR: The COX-2 inhibitor Parecoxib does not enhance the therapeutic efficacy of RIT of experimental small volume peritoneal carcinomatosis of colonic origin.